Financial Data and Key Metrics Changes - Total revenue for the first quarter of 2025 was $112 million, a decrease of 5.2% in reported rates and a decline of 4.1% in constant currency [18] - Adjusted EBITDA was $17.6 million, translating to a 15.7% adjusted EBITDA margin, reflecting a 41% increase year-over-year [22] - Adjusted earnings per share attributable to continuing operations was $0.27, a 238% increase from $0.08 in the prior year period [23] Business Line Data and Key Metrics Changes - Dental implant sales declined low single digits in Q1, consistent with the overall market performance, but showed improvement in March and April [10][11] - Biomaterials portfolio grew just over 1% during the quarter, reflecting ongoing investments in innovation [13] - Digital dentistry business, excluding oral scanner sales, grew high single digits, with the implant concierge service growing 11% year-over-year [14] Market Data and Key Metrics Changes - U.S. net sales were $65.8 million, a decline of 2.8% compared to the prior year, driven by lower implant sales and oral scanners [19] - International net sales were $46.2 million, a decrease of 8.5% on a reported basis, impacted by lower implant sales and headwinds from various factors [20] - Normalized sales outside the U.S. declined 1.6% in constant currency when accounting for specific headwinds [42] Company Strategy and Development Direction - The company is focused on improving and streamlining manufacturing and supply chain processes while reducing corporate infrastructure [6] - A new Vice President of Americas Sales has been appointed to enhance the sales process and expand the customer base [7] - The company is prioritizing higher-margin implant and digital sales over lower-margin distributed products [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the dental market's resilience and the potential for growth in dental implants, which are still under-adopted [66] - The company anticipates continued margin improvement and cash flow generation, aiming to deliver shareholder value [6] - Management reiterated full-year 2025 revenue guidance of $445 million to $460 million, reflecting a 1% decline to 2% growth [25] Other Important Information - The company made a strategic acquisition of a distributor partner in Costa Rica, expected to enhance local market presence and reduce third-party selling costs [16][24] - The company has plans in place to mitigate tariff costs estimated at $3 million per year, largely due to EU-USA tariff rates [6][27] Q&A Session Summary Question: Can you provide more details on the uptick in implant units sold in April? - Management noted that April showed resilience with improved same-store sales and growth in implant units sold, particularly from the new immediate molar implant launch [34] Question: How is pricing trending in the dental market? - Management indicated that the premium implant market has been less price competitive, with selective pricing strategies in place to offset tariff impacts [36][37] Question: What are the reasons for the greater decline in international sales compared to the U.S.? - Management highlighted several headwinds affecting international sales, including foreign exchange impacts and a focus shift away from China [42] Question: What is the current position in the Japanese market? - Management stated that the company has a strong market position in Japan, with the implant concierge expected to drive significant revenue growth [45][47] Question: What actions have been taken to strengthen the supply chain? - Management expressed confidence in manufacturing capabilities and flexibility, having moved significant operations to mitigate tariff risks [58][60]

Core Viewpoint - ZimVie Inc. has launched its Immediate Molar Implant System in the United States, enhancing its existing TSX and T3 PRO Implant systems to address the complexities of molar tooth restoration, thereby reducing treatment times and improving patient outcomes [1][4]. Group 1: Product Features - The Immediate Molar Implant System includes specially engineered instrumentation that simplifies site preparation during molar extraction, making the procedure more controlled and predictable [2]. - The system features optimized wide-diameter implants that enhance primary stability and potentially reduce the risk of peri-implantitis by up to 20% through proprietary DAE coronal surface technology [2]. - Compared to conventional treatment protocols, the Immediate Molar Implant System allows for restoration in half the time, streamlining the overall treatment process [3]. Group 2: Company Commitment - The launch of the Immediate Molar Dental Implant System represents a significant milestone in ZimVie's commitment to advancing dental technology, aiming to provide shorter and more cost-effective treatment options while ensuring predictable and lasting outcomes for patients [4]. - ZimVie has a history of developing products like the TSX and T3 PRO Implants, which are designed for immediate extraction and loading protocols, ensuring placement predictability and primary stability [5][8]. Group 3: Market Position - ZimVie is positioned as a global leader in the dental implant market, focusing on comprehensive solutions for dental tooth replacement and restoration procedures, with a commitment to improving clinical science and technology [10].